AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTX

0.00

AN2 Therapeutics (NASDAQ: ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year.